Alpha-glucosidase Inhibitors Market Regional Analysis:
North America Market Insights
North America industry is expected to dominate majority revenue share of 40.7% by 2035, owing to the high prevalence of type 2 diabetes and advancements in drug production. The region has a strong presence of antidiabetic drug producers and advanced research and treatment organizations, which is positively influencing the sales of alpha-glucosidase inhibitors.
The U.S. market for alpha-glucosidase inhibitors was valued at USD 1.2 billion in 2023 and is expected to expand at a steady CAGR during the forecasted period. According to a 2024 report published by the Centers for Disease Control and Prevention (CDC) states that more than 38 million individuals have diabetes with type 2 diabetes accounting for 90% to 95% of the total. Although type 2 diabetes primarily affects those 45 years of age and older, it is also increasingly occurring in children, teenagers, and young adults.
Improved patient education about diabetes management options and access to healthcare services in the country enhances the likelihood of prescribing alpha-glucosidase inhibitors.
Canada is witnessing a rising prevalence of diabetes that is augmenting the need for advanced therapeutics such as alpha-glucosidase inhibitors. For instance, according to Diabetes Canada, 30% of the individuals in the country are living with diabetes. Moreover, rise in clinical research in Canada is crucial for validating and enhancing the role of alpha-glucosidase inhibitors in diabetes management, ultimately driving market growth and adoption.
APAC Market Insights
Asia Pacific region is expected to register significant growth till 2035, owing to the increased healthcare expenditure. Several governments in the region are highly investing in advancing their healthcare infrastructure, which is set to drive the sales of antidiabetic drugs including alpha-glucosidase inhibitors. India, Japan, South Korea, and China are some of the top markets for alpha-glucosidase inhibitors in the region.
India is foreseen to witness high sales of alpha-glucosidase inhibitors owing to the growing cases of diabetes and rising government initiatives. India is home to the world's second highest number of diabetic patients. According to the National Center for Disease Control, Government of India, the country is projected to have 1.09 billion diabetes cases by 2035. Non-communicable diseases cause 9.8 million fatalities in the country, with diabetes accounting for 2% of total deaths each year.
Additionally, government health programs such as National Diabetes Control Program aims at managing diabetes and promoting preventive healthcare thus, contributing to the increased use of diabetes medications such as alpha-glucosidase inhibitors.
